Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Lisaftoclax on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Lisaftoclax is a targeted tablet for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL), two forms of the same slow-growing blood cancer. It was discovered and developed in China by Ascentage Pharma, where it is sold under the brand name 利生妥® (Chinese generic name 利沙托克拉, research code APG-2575).
China's National Medical Products Administration (NMPA) granted it conditional approval in July 2025 for adults with:
It is a prescription blood cancer medicine and should only be started and monitored by a haematologist.
CLL cells survive far longer than they should because they make too much of a protein called BCL-2, which blocks the cell's built-in self-destruct programme (apoptosis). Lisaftoclax is a small molecule that selectively blocks BCL-2, so the cancer cells lose that protection and die off. It is the first BCL-2 inhibitor developed in China to reach the market, and the company describes it as the second BCL-2 inhibitor approved anywhere in the world.
The approval rests on a registrational phase 2 study (APG2575CC201, NCT05147467) of lisaftoclax on its own in people whose CLL/SLL had come back or stopped responding. Most were hard to treat: 87% no longer responded to a BTK inhibitor and 39% had high-risk del(17p) or TP53 changes. Results presented at the 2025 ASH meeting (77 enrolled, 72 evaluable) showed:
It is taken by mouth once a day. In the pivotal study, patients started on a short daily ramp-up and then took a target dose of 600 mg once daily, in 28-day cycles. The Chinese prescribing information sets out the exact ramp-up steps and tablet strengths, and your haematologist will plan the doses and blood tests for the first weeks.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Blood counts: the main serious side effects in the pivotal study were low blood counts. Severe (grade 3 or higher) neutropenia occurred in 27.3% of patients, low platelets in 16.9% and anaemia in 9.1%. Blood counts are checked regularly, especially early on, and the dose can be paused or adjusted.
Overall: lisaftoclax has conditional approval, which means the company must confirm its benefit in further studies; phase 3 trials are under way. Safety in pregnancy, breastfeeding and children has not been established in the published data.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and it has not been approved by the US FDA or the European Medicines Agency.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For another import option in previously treated CLL, see our page on Jaypirca.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Because treatment starts with a ramp-up, the first order covers the starting doses and later orders the daily target dose, so we plan quantities with the haematologist. The tablets travel in their sealed original packs under temperature-controlled shipping and are stored as directed on the pack. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid specialist's prescription.
Large haematology departments here see many CLL patients from North India, and our New Delhi dispatch point keeps transit times short.
Tablets can be delivered to the patient or to the hospital pharmacy before the ramp-up begins.
Haematologists in Bangalore can request the medicine for a named patient, with the quote shared before anything is ordered.
A major referral centre for blood cancers in South India, with experience in import paperwork for unapproved medicines.
We time the first delivery so the patient can start the ramp-up on the day the doctor plans.
Patients in Kolkata and the eastern states can use the same documented route, with tracking at each stage.
Families in Pune receive regular updates from prescription check to delivery.
The treating haematologist can send us the prescription and treatment history to begin the import.
Patients treated at hospitals in Vellore can have refills planned ahead so there is no gap in daily dosing.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to home or hospital.
We coordinate supply for patients treated at public and private cancer hospitals across Uttar Pradesh.
Patients across Kerala can receive the tablets in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
